Coronavirus In Riverside County: Updated Data

RIVERSIDE COUNTY, CA — Riverside County’s coronavirus positivity rate has climbed to 5.6 percent amid a significant increase in the volume of people being tested countywide, health officials told the Board of Supervisors this week.

According to Department of Public Health Director Kim Saruwatari, the county’s testing rate has reached 221.6 tests per 100,000 population, compared to 195.5 tests per 100,000 a week ago. The state’s testing threshold for large counties is 239.1 per 100,000.

“There’s been a tremendous amount of effort to increase testing in the county,” Saruwatari told the board on Tuesday.

With the increase in screening, there has been a proportional rise in positive results. The 5.6 percent positivity rate compares to an overall rate of 5.2 percent last week.

Additionally, the daily COVID-19 case rate in Riverside County is now 10.1 infections per 100,000 population, according to state data. The previous rate calculated by the state on Oct. 20 was 9.1 per 100,000.

The high case rate and below-threshold testing make the county ineligible for movement back into the “red tier” under the California Department of Public Health’s parameters. On Oct. 20, the CDPH reclassified the county in the “purple tier,” the most restrictive under the state’s color-coded coronavirus regulatory framework, meaning some businesses that had reopened in recent weeks were required to close again or move outdoors, though the compliance level was unknown. The designation impacts gyms, restaurants, movie theaters and places of worship, which can still operate outdoors only.

The total number of COVID-19 infections recorded since the public health documentation period began in early March increased Wednesday by 306 to 67,299, compared to 66,993 on Tuesday, according to the Riverside University Health System. The number of verified patient recoveries is 59,909.

The RUHS reported two additional deaths tied to COVID-19, bringing the county’s death toll from the virus to 1,305.

The number of COVID-positive hospitalizations is now 143 compared to 166 on Tuesday. The figure includes 32 intensive care unit patients, a decrease of 26 since Tuesday.

All COVID-19 hospitalization counts are currently at or below levels reported in April, and Emergency Management Director Bruce Barton told the board Tuesday that “hospitals have resumed normal operations.”

He additionally said that temporary overflow COVID-19 emergency treatment facilities at the Indio Fairgrounds and the shuttered Sears building on Arlington Avenue in Riverside had been “broken down” and the equipment stored in a warehouse for lack of need.

—City News Service contributed to this report.

This article originally appeared on the Temecula Patch

Source Article

Read more

Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer

Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), today announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer. The results confirm achievement of the primary endpoints of safety and tolerability and indicate encouraging initial signals of long-term survival benefit.

“Ultimovacs has established a growing body of clinical data demonstrating a strong safety and tolerability profile for UV1 and a range of preliminary efficacy signals in several cancer indications, all of which supports the further development of our proprietary cancer vaccine candidate,” stated Carlos de Sousa, Chief Executive Officer at Ultimovacs. “The long-term follow-up results announced today demonstrate that treatment with UV1 is safe both at the time of administration and throughout the follow-up period of at least 5 years. Non-small cell lung cancer highly expresses telomerase and remains an indication in great need of new treatment options for patients.”

In the study, a total of 18 non-small cell lung cancer patients whose disease had not progressed after receiving at least 2nd line treatment with chemotherapy were enrolled to receive UV1 monotherapy as maintenance treatment. Outcomes of the study included the safety and tolerability of UV1 as well as initial signs of clinical response. As per the cut-off date of June 2020, every patient in the trial reached at least 60-months of follow-up post treatment with UV1. At the five-years landmark, the Overall Survival (OS) rate was 33% and median Progression Free Survival (mPFS) was 10.7 months. Throughout the follow-up period, none of the patients experienced unexpected safety issues related to UV1. Further, none of the patients alive after 5 years have received other immunotherapy after the vaccination with UV1.

“At the time of the study initiation, there were no checkpoint inhibitors available for treatment of this patient population. For patients that received a second-line of chemotherapy the expected 5-year survival rate was less than 5 percent,” stated Jens Bjørheim, Chief Medical Officer at Ultimovacs. “While our Phase I study is non-randomized and conducted in a small population, it is promising to see that UV1 was safe and well-tolerated and that using UV1 as a maintenance therapy could potentially provide benefit to patients in need of novel approaches.”

Ultimovacs presented 48-months of follow-up data at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting in November of last year.

About UV1

UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immunotherapy which requires an ongoing T cell response for their mode of action. To date, UV1 has been tested in four phase I clinical trials in a total of 82 patients and maintained a positive safety and tolerability profile as well as encouraging signals of efficacy.

About UV1 Clinical Programs

As a universal cancer vaccine, UV1’s unique mechanism of action has the potential to

Read more
  • Partner links